a public good project by the
Synthesis
Company
of California

© 2026

Aleksandr Petrov | doi.page

0 works0 citations0 h-index

Aleksandr Petrov

Togliatti State University(RU)State Research Institute of Highly Pure Biopreparations(RU)

Publications by Year

Research Areas

Diabetes Treatment and Management, Neuropeptides and Animal Physiology, Peptidase Inhibition and Analysis, Pancreatic function and diabetes, Laser-Matter Interactions and Applications

Most-Cited Works

→ (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2004)814 cited
→ Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes(2005)490 cited
→ Targeting a ceramide double bond improves insulin resistance and hepatic steatosis(2019)437 cited
→ Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice(2009)405 cited
→ Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy(2017)331 cited
→ Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia(2011)212 cited

→ Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes(2014)167 cited

→ Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice(2008)164 cited

→ Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes(2009)133 cited

→ (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2006)121 cited